FDA approves Ascensia’s app-enabled blood glucose monitoring system

PARSIPPANY, N.J. — Ascensia Diabetes Care announced Monday that the Food and Drug Administration had approved the company’s Contour Next One blood glucose monitoring system. The blood glucose smart meter can connect to mobile devices via Bluetooth to facilitate easier management within the Contour Diabetes app. 

 

“This is an innovative new option for people living with diabetes,” Ascensia head of U.S. diabetes Robert Schumm said. “The system combines the remarkable accuracy of the Contour Next One meter with the easy-to-use features of the Contour Diabetes app and is designed to provide insights that may help people manage their diabetes in a better way."

 

The Contour Diabetes app collects, stores and analyzes patient blood glucose measurements received from the meter. They can be used to identify patterns and trends that could help patients better understand how their daily activities affect their blood glucose. 

 

“We believe the future of healthcare lies in connecting points of care. The first step in that journey for diabetes is to provide a connected system which can add value for people living with diabetes,” Schumm said. “Today, fewer than two percent of people living with diabetes use a connected meter. Contour Next One is designed to be simple-to-use, and can meet the needs of a broad group of users. The FDA clearance paves the way to providing this option for all those who may benefit from it.”

 

The system includes a smartLIGHT that to provides instant feedback on results, reminders and alerts and a logbook where patients can record meals, activities and medication. Patients can also set up an online account to manage and store their data, as well as have email a PDF summary to their caregiver or healthcare professional. 

 

Ascensia said it planned to make the Contour Next One system available in the United States in early 2017 and the Contour Diabetes app will available in the Apple App Store and Google Play store.